IceCure Medical Ltd (NASDAQ:ICCM) Q1 2025 Earnings Conference Call May 28, 2025 10:00 AM ET
Company Participants
Michael Polyviou – IR
Eyal Shamir – CEO
Ronen Tsimerman – CFO and COO
Conference Call Participants
Anthony Vendetti – Maxim Group
Kemp Dolliver – Brookline Capital Markets
Operator
Good morning, and thank you for standing by. Currently, all the participants are in a listen-only mode. After management’s discussion, there will be a question-and-answer session. Please be advised that today’s conference is being recorded. I would now like to turn the conference over to Michael Polyviou. Please go ahead.
Michael Polyviou
Thank you, Joni, and welcome to IceCure Medical’s conference call to review the financial results as of and for the three months ended March 31, 2025, and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning. Participating on today’s call are IceCure Medical’s CEO, Eyal Shamir; and the company’s CFO and COO, Ronen Tsimerman.
Before we begin, I will now take a moment to read a statement about forward-looking statements. This call and the question-and-answer session that follows it contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements in this presentation when we discuss our prospective post-market study plan and our beliefs and expectations following our meeting with the FDA at the end of April. The expectation of the FDA’s final marketing authorization decision for ProSense upon approval of the post-market study plan, our plan to commence commercial sales in parallel with running our post-market study, our belief that additional reimbursements may become available based on regulatory
#IceCure #Medical #ICCM #Earnings #Call #Transcript